fbpx

molecules of the month

GB0139

inhaled galectin-3 inhibitor

Ph. II for IPF + Ph. Ib/IIa for COVID-19 pneumonitis

synthetic galactoside derivative

medRxiv, January 10, 2022

Galecto, Inc., Copenhagen, DE

GB0139, TD139, olitigaltin inhaled galectin-3 inhibitor Ph. II for IPF + Ph. Ib/IIa for COVID-19 pneumonitis synthetic galactoside derivative Galecto Inc., Copenhagen, DK
3 mins read

What is it? GB0139 is a selective, inhaled inhibitor of galectin-3 and galectin-1 in Ph. II for IPF and COVID-19 pneumonitis, and is Galecto’s ($GLTO) lead asset. Galecto was founded in 2011 with Lund University academic galectin research leaders Ulf Nilsson and Hakon Leffler, and has had a research focus on galectin-3 modulators to treat fibrotic diseases. We recently covered another Galecto development compound, GB1211, a related oral galectin-3 inhibitor, Ph. I/II candidate, and September 2022 Molecule of the Month. With the 2022 Nobel Prize in Chemistry awarded for “click chemistry,” this molecule is an interesting example of a development candidate derived from an azide-alkyne cycloaddition. Galectin-3 as a target. Galectins are a relatively underexplored target class, despite academic research…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: